Chronic Pancreatitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Chronic Pancreatitis Market Outlook

Thelansis’s “Chronic Pancreatitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pancreatitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Pancreatitis Overview

Chronic pancreatitis is a progressive inflammatory condition that results in the irreversible destruction of both exocrine and endocrine pancreatic tissue, typically due to atrophy or its replacement with fibrous tissue. This disorder gives rise to significant functional consequences, including intense abdominal pain, diabetes mellitus, and malabsorption of nutrients. Chronic pancreatitis can be triggered by various factors, including alcohol abuse, blockage of the pancreatic ducts (caused by malignancies, stones, or trauma), genetic predisposition, chemotherapy, and autoimmune diseases such as systemic lupus erythematosus (SLE) or autoimmune pancreatitis. Laboratory tests used for diagnosing chronic pancreatitis encompass a complete blood count (CBC), basic metabolic panel (BMP), liver function tests (LFTs), lipase, amylase, lipid panel, and measurement of fecal elastase-1 levels. Lipase and amylase levels may exhibit elevation, although they tend to be normal due to significant pancreatic scarring and fibrosis. The primary goal of treatment includes reducing abdominal pain and addressing malabsorption. The pain experienced by individuals with chronic pancreatitis arises from inflammation, neuropathic mechanisms, and obstructed ducts. Dietary recommendations typically involve consuming small, frequent, low-fat meals and supplementing fat-soluble vitamins and pancreatic enzymes. Surgical intervention to resect the pancreas can yield positive outcomes when performed by experienced surgeons. However, it’s worth noting that the procedure carries a mortality rate exceeding 10%, and the quality of life is compromised without a properly functioning pancreas. In cases where there is persistent and worsening abdominal pain, a comprehensive differential diagnosis is considered. This includes conditions such as peptic ulcer disease, cholelithiasis, biliary obstruction or colic, acute pancreatitis, pancreatic malignancy, pseudocyst formation, and chronic mesenteric ischemia. The prognosis for chronic pancreatitis is significantly affected by ongoing alcohol use, smoking, and end-stage liver disease. Ten years after diagnosis, there is a survival rate of 70%, which decreases to 45% at the 20-year mark. Notable complications include pseudocyst formation and mechanical obstructions of the bile duct and duodenum.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Chronic Pancreatitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034